Thursday, March 7, 2013


*Avastin-Folfoxiri better than Avastin-Folfiri, no news there.  It is just a repeat of things we knew would happen.
*In Colon cancer patients with Wild type KRAS  Panitumumab (Vectibix) associated to 5-FU based combination gave an outcome comparable to results obtained in a different study with Avastin and 5-FU based combination.  2 phase II trials but 2 similar outcomes.   And this in first line and 2nd line.  Can't wait to see a phase III.
*40% Glioblastoma express EGFR
20% have EGFRvIII
with Lapatinip being looked at for treatment, will wait to see.

Post a Comment